



## Organic Preparations and Procedures International: The New Journal for Organic Synthesis

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/uopp20>

### A NOVEL SYNTHESIS OF 3-SUBSTITUTED MDAZOLIDIN-2-ONE-1-CARBONYL CHLORIDES

Weike Su <sup>a</sup>, Kewei Huang <sup>a b</sup> & Yongmin Zhang <sup>c</sup>

<sup>a</sup> Department of Pharmaceutical Engineering, Zhejiang University of Technology, Hangzhou, 310014, PR China

<sup>b</sup> Department of Science and Technology, Zhejiang University of Radio and Television, Hangzhou, 310012, PR China

<sup>c</sup> Department of Chemistry, Zhejiang University, Campus Xixi, Hangzhou, 310028, PR China

Published online: 18 Feb 2009.

To cite this article: Weike Su, Kewei Huang & Yongmin Zhang (2009): A NOVEL SYNTHESIS OF 3-SUBSTITUTED MDAZOLIDIN-2-ONE-1-CARBONYL CHLORIDES, *Organic Preparations and Procedures International: The New Journal for Organic Synthesis*, 32:5, 498-501

To link to this article: <http://dx.doi.org/10.1080/00304940009356767>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.tandfonline.com/page/terms-and-conditions>

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

## A NOVEL SYNTHESIS OF 3-SUBSTITUTED IMIDAZOLIDIN-2-ONE-1-CARBONYL CHLORIDES

Submitted by                      Weike Su<sup>a,c</sup>, Kewei Huang<sup>b</sup> and Yongmin Zhang<sup>\*c</sup>  
(05/31/00)


<sup>a</sup>*Department of Pharmaceutical Engineering  
Zhejiang University of Technology  
Hangzhou, 310014, P.R. China*

<sup>b</sup>*Department of Science and Technology  
Zhejiang University of Radio and Television  
Hangzhou, 310012, P.R. China*

<sup>c</sup>*Department of Chemistry, Zhejiang University (Campus Xixi)  
Hangzhou, 310028, P.R. China*


3-Substituted imidazolidin-2-one-1-carbonyl chlorides (SICs) are very important intermediates for the semi-synthesis of  $\beta$ -lactam antibiotics.<sup>1-6</sup> SICs have been conveniently prepared by the reaction of *N*-substituted imidazolidin-2-ones with phosgene.<sup>1-5</sup> However, phosgene has become commercially inaccessible as a common and useful reagent because it is a highly toxic, dangerous gas. Such a situation prompted us to investigate a substitute for phosgene in the synthesis of SICs.

Trichloromethyl chloroformate (TCF) has been known as a phosgene dimer and used as a substitute for phosgene in industry.<sup>7-12</sup> We found that TCF can replace phosgene in the synthesis of SICs and the reaction is shown in *Scheme 1*. The role of pyridine is to promote the decomposition of TCF to phosgene and to intercept the by-product HCl. Our experiment showed that without pyridine, the reaction time would be longer and the yield would be lower.



**Scheme 1**

A possible mechanism may be proposed as shown in *Scheme 2*. TCF undergoes nucleophilic attack at the carbonyl carbon; the trichloromethoxy (Cl<sub>3</sub>CO<sup>-</sup>) leaving group decomposes to the chloride anion and a molecule of phosgene, which reacts immediately with another molecule of *N*-substituted imidazolidin-2-one. As the reaction proceeds, the evolved HCl is trapped by pyridine. However, the exact mechanism is not fully clarified and a more detailed study is in progress in our laboratory.

**Table 1** Synthesis of 3-Substituted Imidazolidin-2-one-1-carbonyl Chlorides<sup>a</sup>

Product	R	Solvent	Reaction time (h)	Purity (%) <sup>b</sup>	Yields (%) <sup>c</sup>
<b>2a</b>	MeSO <sub>2</sub>	CHCl <sub>3</sub>	2-3 ( <i>lit.</i> <sup>3</sup> 72) <sup>d</sup>	99.5	85 ( <i>lit.</i> <sup>3</sup> 70)
<b>2b</b>	EtSO <sub>2</sub>	Cl(CH <sub>2</sub> ) <sub>2</sub> Cl	2-3 ( <i>lit.</i> <sup>3</sup> 72) <sup>d</sup>	99.4	80
<b>2c</b>	MeCO	C <sub>6</sub> H <sub>6</sub>	2 ( <i>lit.</i> <sup>3</sup> 18) <sup>d</sup>	99.6	92 ( <i>lit.</i> <sup>3</sup> 81)
<b>2d</b>	MeOCO	C <sub>6</sub> H <sub>6</sub>	2 ( <i>lit.</i> <sup>3</sup> 18) <sup>d</sup>	99.5	88 ( <i>lit.</i> <sup>3</sup> 72)
<b>2e</b>	PhSO <sub>2</sub>	CHCl <sub>3</sub>	3-4	99.0	80 ( <i>lit.</i> <sup>2</sup> 64)
<b>2f</b>	NC(CH <sub>2</sub> ) <sub>2</sub> CO	CHCl <sub>3</sub>	2-3	98.8	60 ( <i>lit.</i> <sup>2</sup> 44)
<b>2g</b>	<i>m</i> -CNC <sub>6</sub> H <sub>4</sub>	THF	2 ( <i>lit.</i> <sup>6</sup> 20) <sup>d</sup>	98.5	79 ( <i>lit.</i> <sup>6</sup> 59.8)
<b>2h</b>	<i>m</i> -ClC <sub>6</sub> H <sub>4</sub>	THF	2 ( <i>lit.</i> <sup>6</sup> 20) <sup>d</sup>	98.7	81 ( <i>lit.</i> <sup>6</sup> 65.5)
<b>2i</b>	<i>p</i> -MeOC <sub>6</sub> H <sub>4</sub>	THF	2 ( <i>lit.</i> <sup>6</sup> 20) <sup>d</sup>	99.0	78 ( <i>lit.</i> <sup>6</sup> 64)
<b>2j</b>	<i>o</i> -MeOC <sub>6</sub> H <sub>4</sub>	THF	2 ( <i>lit.</i> <sup>6</sup> 20) <sup>d</sup>	99.1	76 ( <i>lit.</i> <sup>6</sup> 60)

a) All reactions were carried out at the same molar ratio, *i.e.* *N*-substituted imidazolidin-2-ones : TCF = 1 : 0.55. b) HPLC purity. c) Isolated yields based on *N*-substituted imidazolidin-2-ones. d) Time required in literature cited with phosgene.

The amount of TCF needed for complete reaction with *N*-substituted imidazolidin-2-ones has been examined. Theoretically, a half mole of TCF should be sufficient to react with a mole of the *N*-substituted imidazolidin-2-one, because one mole of TCF yields two moles of phosgene. However, even when a 5 mol% excess of TCF was allowed to react with *N*-substituted imidazolidin-2-ones, 10% of the *N*-substituted imidazolidin-2-one was left still unreacted. The use of 10% excess of TCF led total conversion to SICs and the results are summarized in *Table 1*.

Table 1 shows that the phosgenation reaction is completed within 2-3 hours and gives SICs in high yields. However, the use of phosgene requires a several-fold excess and even then, the yields are often only moderate. Furthermore, owing to the relatively low-volatility of TCF, only the usual safety precautions are necessary.

## EXPERIMENTAL SECTION

Melting points were obtained in a capillary melting point apparatus and are uncorrected. Infrared spectra were recorded on an IR-408 spectrometer as KBr pellet ( $\text{cm}^{-1}$ ).  $^1\text{H}$  NMR spectra were determined in a Bruker AC-80 spectrometer using TMS as internal standard. The purity of products was determined on Bio-rad HPLC (Column: GL sciences Inc. Inertsil ODS-80A 4.6 x 250 nm; mobile phase:  $\text{CH}_3\text{CN} : \text{H}_2\text{O} : \text{KH}_2\text{PO}_4$  (w/w/w)= 32 : 60 : 0.2; flow rate: 1 mL/min).

**General Procedure for the Preparation of SICs Using TCF.**— Into a 4-neck 250 mL reaction vessel fitted with a heating mantle, a reflux condenser, a thermometer, a stirrer and a graduated addition funnel was charged 75 mL of dry solvent (*Table 1*), 8.8 mL (0.11 mol) of pyridine and 0.1 mol of *N*-substituted imidazolidin-2-one. The suspension was heated to  $50^\circ$ , and then 6.6 mL (0.55 mol) of TCF was added dropwise over the course of 1 hr. to the suspension at such a rate that the internal temperature was  $50$ – $55^\circ$ . The mixture was then stirred further at  $55^\circ$  (see *Table 1*), then cooled to  $20^\circ$  until crystals precipitated completely. The crude product was recrystallized from 120 mL of the boiling recrystallization solvent.

**2a**, light yellow crystal, mp  $179$ – $180^\circ$  (acetone, *lit.*<sup>3</sup>  $178^\circ$ ). IR ( $\text{cm}^{-1}$ ): 1810, 1718, 1360, 1160.  $^1\text{H}$  NMR: d 3.41 (3H, s,  $\text{CH}_3$ ), 3.81–4.39 (4H, m, 2 x  $\text{CH}_2$ ).

**2b**, light pale crystal, mp  $175$ – $175.5^\circ$  (acetone, *lit.*<sup>3</sup>  $174^\circ$ ). IR ( $\text{cm}^{-1}$ ): 1812, 1722, 1350, 1170.  $^1\text{H}$  NMR: d 1.45 (3H, t,  $J=3.8\text{Hz}$ ,  $\text{CH}_3$ ), 3.60 (2H, q,  $J=3.8\text{Hz}$ ,  $\text{CH}_2$ ), 3.96–4.40 (4H, m, 2 x  $\text{CH}_2$ ).

**2c**, light pale crystal, mp  $104$ – $104.5^\circ$  (acetone/petroleum ether, *lit.*<sup>3</sup>  $104^\circ$ ). IR ( $\text{cm}^{-1}$ ): 1800, 1742, 1692, 1665.  $^1\text{H}$  NMR: d 2.60 (3H, s,  $\text{CH}_3$ ), 3.80–4.40 (4H, m, 2 x  $\text{CH}_2$ ).

**2d**, light yellow crystal, mp  $129$ – $130^\circ$  (acetone/ petroleum ether, *lit.*<sup>3</sup>  $129^\circ$ ). IR ( $\text{cm}^{-1}$ ): 1818, 1740, 1695, 1265.  $^1\text{H}$  NMR: d 3.94 (3H, s,  $\text{CH}_3\text{O}$ ), 3.77–4.40 (4H, m, 2 x  $\text{CH}_2$ ).

**2e**, light yellow crystal, mp  $161$ – $162^\circ$  (acetone/ petroleum ether, *lit.*<sup>2</sup>  $161^\circ$ ). IR ( $\text{cm}^{-1}$ ): 1800, 1730, 1320, 1200.  $^1\text{H}$  NMR: d 3.95–4.35 (4H, m, 2 x  $\text{CH}_2$ ), 7.61–8.18 (5H, m, PhH).

**2f**, light yellow crystal, mp  $127$ – $130^\circ$  (dec.) (acetone, *lit.*<sup>2</sup>  $127$ – $130^\circ$ ). IR ( $\text{cm}^{-1}$ ): 2250, 1798, 1718, 1690.  $^1\text{H}$  NMR: d 2.90 (2H, t,  $J=5.0\text{Hz}$ ,  $\text{CH}_2$ ), 3.12 (2H, t,  $J=5.0\text{Hz}$ ,  $\text{CH}_2$ ), 3.83–3.90 (4H, m, 2 x  $\text{CH}_2$ ).

**2g**, light yellow crystal, mp  $138$ – $138.5^\circ$  (ethyl acetate, *lit.*<sup>6</sup>  $136^\circ$ ). IR ( $\text{cm}^{-1}$ ): 2230, 1822, 1722.  $^1\text{H}$  NMR: d 3.82–4.10 (4H, m, 2 x  $\text{CH}_2$ ), 7.06–7.95 (4H, m, ArH).

**2h**, light yellow crystal, mp  $209$ – $210^\circ$  (ethyl acetate, *lit.*<sup>6</sup>  $208^\circ$ ). IR ( $\text{cm}^{-1}$ ): 1821, 1702.  $^1\text{H}$  NMR: d 3.80–4.10 (4H, m, 2 x  $\text{CH}_2$ ), 6.96–7.86 (4H, m, ArH).

**2i**, light yellow crystal, mp  $183$ – $183.5^\circ$  (toluene, *lit.*<sup>6</sup>  $182$ – $183^\circ$ ). IR ( $\text{cm}^{-1}$ ): 2850, 1815, 1707.  $^1\text{H}$  NMR: d 3.60 (3H, s,  $\text{CH}_3\text{O}$ ), 3.70–4.10 (4H, m, 2 x  $\text{CH}_2$ ), 7.06–7.25 (4H, m, ArH).

**2j**, light yellow crystal, mp 90-91° (toluene, *lit.*<sup>6</sup> 88-91°). IR (cm<sup>-1</sup>): 2845, 1799, 1700. <sup>1</sup>H NMR: δ 3.90 (3H, s, CH<sub>3</sub>O), 3.60-4.10 (4H, m, 2 x CH<sub>2</sub>), 6.74-7.35 (4H, m, ArH).

## REFERENCES

1. W. Schroeck, H. B. Koenig and K. G. Metzger, *Ger. Offen 2,104,580*; *Chem. Abstr.*, **82**, 31313b (1970).
2. W. Schroeck, H. B. Koenig, M. Preiss and K. G. Metzger, *Ger. Offen 2,407,715*; *Chem. Abstr.*, **84**, 4975d (1975).
3. H. B. Koenig, W. Schroeck and K. G. Metzger, *Ger. Offen 2,152,968*; *Chem. Abstr.*, **79**, 18697y (1971).
4. L. Novak, *CS 218,031*; *Chem. Abstr.*, **104**, 148873y (1985).
5. P. H. Milner, *EP 114,752*; *Chem. Abstr.*, **102**, 6047s (1984).
6. H. B. Koenig, K. G. Metzger and W. Schroeck, *Ger. 2,528,079*; *Chem. Abstr.*, **86**, 189918v (1975).
7. V. V. Nekrasov and N. N. Melnikov, *J. prakt. Chem.*, **126**, 81 (1930).
8. Heilbron, H. M. Bunbury and D. H. Hey, "*Dictionary of Organic Compounds*", Vol. 5, Eyre & Spottiswoode publishers Ltd., p. 3116 (1965).
9. M. Oya, R. Katakai and H. Nakai, *Chemistry Lett.*, 1143 (**1973**).
10. R. Katakai and Y. Iizuka, *J. Org. Chem.*, **50**, 715 (1985).
11. Y. Koiwa, K. Tatsukawa, A. Miike, M. Teranish and Y. Fujimoto, *J. Synth. Org. Chem. Jpn.*, **33**, 628 (1975).
12. H. Babad and A. G. Zeiler, *Chem. Rev.*, **73**, 75 (1973).